MedWatch

Bank: Choose this European company over Lilly

Eli Lilly has raised expectations for 2013 more than anticipated, but one factor especially has the Danish bank Nordea recommending a European company over the US pharmaceutical group.

Foto: Eli Lilly/PR

In spite of raised expectations for 2013, which exceeded the estimates of most analysts, Nordea does not have a lot of faith in Eli Lilly.

“It is certainly positive, but ahead – in December – lies he patent expiration of one of their best selling products, the antidepressant Cymbelta, which produced a turnover of 4.8 billion dollars in 2012. That is a major uncertainty factor from the share and – being relatively high priced – we see better opportunities elsewhere in the sector,” the bank writes in its morning report Monday.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier